Clene 관리

관리 기준 확인 3/4

Clene CEO는 Rob Etherington, Apr2013 에 임명되었습니다 의 임기는 11.58 년입니다. 총 연간 보상은 $ 1.71M, 38.3% 로 구성됩니다. 38.3% 급여 및 61.7% 보너스(회사 주식 및 옵션 포함). 는 $ 256.83K 가치에 해당하는 회사 주식의 0.53% 직접 소유합니다. 256.83K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.9 년입니다.

주요 정보

Rob Etherington

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	38.3%
CEO 임기	11.6yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

Clene slips 13% as lead asset fails in ALS study

Oct 03

CEO 보상 분석

Rob Etherington 의 보수는 Clene 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$2m	US$654k	-US$50m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$2m	US$561k	-US$30m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	US$15m
Mar 31 2022	n/a	n/a	US$17m
Dec 31 2021	US$5m	US$510k	-US$10m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$498k	US$335k	-US$19m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$510k	US$335k	-US$16m
Dec 31 2018	US$465k	US$335k	-US$12m

보상 대 시장: Rob 의 총 보상 ($USD 1.71M )은 US 시장( $USD 655.65K ).

보상과 수익: Rob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rob Etherington (57 yo)

11.6yrs

테뉴어

US$1,706,605

보상

Mr. Robert Etherington, also known as Rob, MBA, serves as Chief Executive officer, President and Director at Clene Nanomedicine, Inc. He serves as President, Chief Executive Officer and Director at Clene...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Etherington	CEO, President & Director	11.6yrs	US$1.71m	0.53% $ 256.8k
Morgan Brown	Chief Financial Officer	2.8yrs	US$993.70k	0% $ 0
Mark Mortenson	Chief Science Officer	no data	US$1.38m	0.36% $ 176.9k
Jerry Miraglia	General Counsel & Corporate Secretary	no data	데이터 없음	데이터 없음
Michael Hotchkin	Chief Development Officer	no data	데이터 없음	데이터 없음
Mary Mcneil	Head of Human Resources	no data	데이터 없음	데이터 없음
Benjamin Greenberg	Head of Medical	1.7yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: CLNN 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Etherington	CEO, President & Director	11.6yrs	US$1.71m	0.53% $ 256.8k
David Matlin	Independent Chairman of the Board	3.9yrs	US$99.65k	5.68% $ 2.8m
Reed Wilcox	Independent Director	11.7yrs	데이터 없음	0.36% $ 175.7k
Jonathon Gay	Independent Director	3.9yrs	US$67.50k	0.11% $ 53.3k
Alison Mosca	Independent Director	5.2yrs	US$82.64k	4.97% $ 2.4m
Arjun Desai	Independent Director	1.2yrs	US$31.09k	0.010% $ 5.0k
Shalom Jacobovitz	Independent Director	11.7yrs	US$81.14k	0.047% $ 22.9k
Matthew Kiernan	Independent Director	1.2yrs	US$29.59k	0.0054% $ 2.6k
Vallerie McLaughlin	Independent Director	3.3yrs	US$65.63k	0% $ 0

3.9yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: CLNN 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

Clene 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Clene Inc., Annual General Meeting, May 29, 2024

Independent Chairman of the Board recently bought US$103k worth of stock

High number of new directors

Clene Inc. Announces Executive Changes

Independent Director recently bought US$253k worth of stock

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Recent updates

New minor risk - Profitability

Consensus revenue estimates decrease by 10%

Clene Inc. announced that it has received $7.31006 million in funding

Consensus revenue estimates increase by 11%

New minor risk - Profitability

Clene Inc. has completed a Follow-on Equity Offering in the amount of $3.499996 million.

Clene Inc. announced that it expects to receive $3.810506 million in funding

Clene Inc. has filed a Follow-on Equity Offering in the amount of $3.499996 million.

Price target decreased by 13% to US$48.00

Second quarter 2024 earnings released: US$1.06 loss per share (vs US$5.84 loss in 2Q 2023)

Price target decreased by 8.8% to US$91.25

New major risk - Share price stability

New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Clene Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2) for Continued Listing on Nasdaq

Consensus revenue estimates increase by 16%

Clene Inc. and Clene Nanomedicine Inc. Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS

Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome

Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg

Consensus revenue estimates fall by 30%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Price target decreased by 11% to US$5.00

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought US$103k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%, EPS downgraded

Price target decreased by 13% to US$5.83

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

New minor risk - Share price stability

Independent Director recently bought US$253k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Price target decreased by 20% to US$6.71

Consensus revenue estimates increase by 21%

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 27%

Consensus revenue estimates decrease by 53%, EPS upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 10% to US$8.57

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$9.57

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board recently bought US$2.9m worth of stock

High number of new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$10.57

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Investor sentiment deteriorated over the past week

Clene slips 13% as lead asset fails in ALS study

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Consensus estimates of losses per share improve by 12%